NCT03446976View on ClinicalTrials.gov

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

July 26, 2018

Study Completion Date

July 26, 2018

Conditions
Health, Subjective
Interventions
BIOLOGICAL

CT-P13 SC Auto-injector

Each subject may receive single dose by subcutaneous administration using Auto-Injector

BIOLOGICAL

CT-P13 SC Pre-filled Syringe

Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY